The National Institute on Deafness and Other Communication Disorderse (NIDCD) is interested in expanding the cadre of basic and clinical scientists who conduct research on otitis media (OM). The purpose of this Notice of Special Interest (NOSI) is to invite Early Stage Investigators (ESIs), as defined by the NIH https://grants.nih.gov/grants/new_investigators/index.htm#earlystage , to submit research applications that focus on OM—commonly known as ear infections. There is a critical need for focused, novel, creative and innovative research approaches that accelerate the development of effective ways to prevent and treat OM.
OM represents a substantial disease burden both in the U.S and globally. This is especially true among underserved populations in underdeveloped countries. Even in the U.S., OM is the most common childhood illness, with more than 90% of children having at least one episode by age 5 and approximately 15% experiencing one of the more serious forms, such as recurrent or chronic OM. The impact of recurrent or chronic OM on a child’s development can be significant, resulting in some cases, in hearing loss and to deficits in speech, language acquisition, learning, and complex auditory processing. Although not common, deaths secondary to OM do occur. While the numbers are thought to be low, that does not diminish the trauma associated with the loss of a child. OM is a current and real and present problem.
Given the serious auditory consequences of OM and of its other sequelae as well as the global healthcare burden, in October 2020, NIDCD convened a virtual workshop on “Otitis Media in Early Childhood“. The goal was to comprehensively assess the status (past and present) as well as the immediate and future research needed to accelerate development of ways to prevention and treat OM. The workshop report can be found at: https://www.nidcd.nih.gov/workshops/2020/summary One of the outcomes of the workshop was a glaring need to increase/reinvigorate the number of NIDCD supported investigators in this area of research.
To begin to rectify this situation:
There is special interest in those applications that bring unique and original approaches with promise to drive/ facilitate clinical translation.
Investigators are strongly encouraged to think in the context of a translational vision of how the proposed experiments could result in a prevention/therapeutic path forward.
This notice applies to due dates on or after January 25, 2022 and subsequent receipt dates through September 8, 2025.
NOT-DC-22-001
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Oct 05, 2024
Varies
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.